Abo Nahas, H.H.; Al-Dakhil, A.; Mohamed, D.I.; Yousef, T.A.; Almaaty, A.H.A.; El-Deen, I.M.; Sembawa, H.A.M.; Saied, E.M.
Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation. Pharmaceuticals 2026, 19, 559.
https://doi.org/10.3390/ph19040559
AMA Style
Abo Nahas HH, Al-Dakhil A, Mohamed DI, Yousef TA, Almaaty AHA, El-Deen IM, Sembawa HAM, Saied EM.
Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation. Pharmaceuticals. 2026; 19(4):559.
https://doi.org/10.3390/ph19040559
Chicago/Turabian Style
Abo Nahas, Hebatallah H., Abdullah Al-Dakhil, Doaa I. Mohamed, Tarek A. Yousef, Ali H. Abu Almaaty, Ibrahium M. El-Deen, Hatem Adel M. Sembawa, and Essa M. Saied.
2026. "Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation" Pharmaceuticals 19, no. 4: 559.
https://doi.org/10.3390/ph19040559
APA Style
Abo Nahas, H. H., Al-Dakhil, A., Mohamed, D. I., Yousef, T. A., Almaaty, A. H. A., El-Deen, I. M., Sembawa, H. A. M., & Saied, E. M.
(2026). Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation. Pharmaceuticals, 19(4), 559.
https://doi.org/10.3390/ph19040559
